These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32363761)

  • 1. Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression.
    Moriya H; Tiger M; Tateno A; Sakayori T; Masuoka T; Kim W; Arakawa R; Okubo Y
    Psychiatry Clin Neurosci; 2020 Aug; 74(8):424-430. PubMed ID: 32363761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
    Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
    Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder: In Vivo Positron Emission Tomography and Postmortem Evidence.
    Pizzagalli DA; Berretta S; Wooten D; Goer F; Pilobello KT; Kumar P; Murray L; Beltzer M; Boyer-Boiteau A; Alpert N; El Fakhri G; Mechawar N; Vitaliano G; Turecki G; Normandin M
    JAMA Psychiatry; 2019 Aug; 76(8):854-861. PubMed ID: 31042280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification and discriminative power of
    Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower midbrain dopamine transporter availability in depressed patients: Report from high-resolution PET imaging.
    Dubol M; Trichard C; Leroy C; Granger B; Tzavara ET; Martinot JL; Artiges E
    J Affect Disord; 2020 Feb; 262():273-277. PubMed ID: 31732277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [
    Masuoka T; Tateno A; Sakayori T; Tiger M; Kim W; Moriya H; Ueda S; Arakawa R; Okubo Y
    Psychiatry Res Neuroimaging; 2020 Jul; 301():111086. PubMed ID: 32464340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
    Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
    Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter imaging with [
    Jakobson Mo S; Axelsson J; Jonasson L; Larsson A; Ögren MJ; Ögren M; Varrone A; Eriksson L; Bäckström D; Af Bjerkén S; Linder J; Riklund K
    EJNMMI Res; 2018 Nov; 8(1):100. PubMed ID: 30443684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.
    Leroy C; Karila L; Martinot JL; Lukasiewicz M; Duchesnay E; Comtat C; Dollé F; Benyamina A; Artiges E; Ribeiro MJ; Reynaud M; Trichard C
    Addict Biol; 2012 Nov; 17(6):981-90. PubMed ID: 21812871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.
    Emond P; Guilloteau D; Chalon S
    CNS Neurosci Ther; 2008; 14(1):47-64. PubMed ID: 18482099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT.
    Jakobson Mo S; Axelsson J; Stiernman LJ; Larsson A; Af Bjerkén S; Bäckström D; Kellgren TG; Varrone A; Riklund K
    Nucl Med Commun; 2022 Mar; 43(3):247-255. PubMed ID: 34908018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with ¹⁸F-FE-PE2I.
    Ikoma Y; Sasaki T; Kimura Y; Seki C; Okubo Y; Suhara T; Ito H
    Ann Nucl Med; 2015 Oct; 29(8):697-708. PubMed ID: 26134215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic dysfunction in the left putamen of patients with major depressive disorder.
    D'Onofrio AM; Pizzuto DA; Batir R; Perrone E; Cocciolillo F; Cavallo F; Kotzalidis GD; Simonetti A; d'Andrea G; Pettorruso M; Sani G; Di Giuda D; Camardese G
    J Affect Disord; 2024 Jul; 357():107-115. PubMed ID: 38636713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study.
    Hjorth OR; Frick A; Gingnell M; Hoppe JM; Faria V; Hultberg S; Alaie I; Månsson KNT; Wahlstedt K; Jonasson M; Lubberink M; Antoni G; Fredrikson M; Furmark T
    Mol Psychiatry; 2021 Aug; 26(8):3970-3979. PubMed ID: 31822819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.